Mega Lifesciences PCL
SET:MEGA
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (12.9), the stock would be worth ฿47.35 (41% upside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 9.1 | ฿33.5 |
0%
|
| 3-Year Average | 12.9 | ฿47.35 |
+41%
|
| 5-Year Average | 14.8 | ฿54.39 |
+62%
|
| Industry Average | 10.9 | ฿40.31 |
+20%
|
| Country Average | 8.5 | ฿31.48 |
-6%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| TH |
M
|
Mega Lifesciences PCL
SET:MEGA
|
29.2B THB | 9.1 | 15.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
930.7B USD | 57.2 | 45.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
581.6B USD | 24.8 | 21.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
254.1B CHF | 15 | 19.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
231.8B CHF | 16.6 | 21.4 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
221.9B GBP | 21.9 | 29.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.1B USD | 19.3 | 15.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 834.6 | -74.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 10 | 10.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.1B USD | 17 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD | 10.7 | 16.9 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 6.1 |
| Median | 8.5 |
| 70th Percentile | 12 |
| Max | 13 428 |
Other Multiples
Mega Lifesciences PCL
Glance View
Mega Lifesciences Public Co. Ltd. engages in the manufacture, market, sale, and distribution of pharmaceutical, nutraceutical products, and consumer goods. The company is headquartered in Bangkok, Bangkok Metropolis. The company went IPO on 2013-11-19. The firm's products include complimentary medicines, over-the-counter (OTC) medicines and prescription medicines to both domestic and international markets. The company distributes products under Maxxcare brand covering prescription pharmaceutical products, OTC drugs and other consumer products. The firm also offers nutritional products, prescription pharmaceutical products and OTC drugs under Mega We Care brand. In addition, the Company operates as an original equipment manufacturer (OEM) for various products including health supplements, pharmaceutical, herbal products, vitamins and minerals, among others.
